Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$50.24−0.86 (-1.68%)
Close on Nov 18, 2026Market cap $4.74BP/E –Yield –
Travere Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Travere Therapeutics's price to sales ratio was 8.3× on Nov 11, 2026, against 7.3× a year earlier. Over the last 5 years it ranged from 2.9× to 13.2×, with a median of 7.8×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 8.3× | +0.4 |
| 2025 | Dec 31, 2025 | 7.8× | +1.2 |
| 2024 | Dec 31, 2024 | 6.7× | +1.5 |
| 2023 | Dec 29, 2023 | 5.2× | −4.6 |
| 2022 | Dec 30, 2022 | 9.8× | +1.3 |
| 2021 | Dec 31, 2021 | 8.6× | +1.4 |
| 2020 | Dec 31, 2020 | 7.2× | +3.6 |
| 2019 | Dec 31, 2019 | 3.5× | −2.2 |
| 2018 | Dec 31, 2018 | 5.7× | +0.2 |
| 2017 | Dec 29, 2017 | 5.5× | −0.1 |
| 2016 | Dec 30, 2016 | 5.6× | −2.7 |
| 2015 | Dec 31, 2015 | 8.3× | – |
See a number that looks wrong?